Invention Grant
US08349820B2 Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido
失效
使用戊酸雌二醇或17和bgr-雌二醇联合去甲肾上腺素进行口服治疗以维持和/或增加女性性欲
- Patent Title: Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido
- Patent Title (中): 使用戊酸雌二醇或17和bgr-雌二醇联合去甲肾上腺素进行口服治疗以维持和/或增加女性性欲
-
Application No.: US11873595Application Date: 2007-10-17
-
Publication No.: US08349820B2Publication Date: 2013-01-08
- Inventor: Susan Zeun , Holger Zimmermann , Susanne Parke
- Applicant: Susan Zeun , Holger Zimmermann , Susanne Parke
- Applicant Address: DE Berlin
- Assignee: Bayer Pharma Aktiengesellschaft
- Current Assignee: Bayer Pharma Aktiengesellschaft
- Current Assignee Address: DE Berlin
- Agency: Millen, White, Zelano & Branigan, PC
- Priority: EP06022091 20061020; EP07009373 20070510
- Main IPC: A61K31/56
- IPC: A61K31/56
Abstract:
The invention relates to the use, optionally together with oral contraception, of estradiol valerate or 17β-estradiol in combination with 17α-cyanomethyl-17-β-hydroxyestra-4,9-dien-3-one (dienogest) in a multistage or single-stage combination preparation for oral therapy to maintain and/or increase feminine libido.The total number of daily dose units of the multistage combination and of a pharmaceutically harmless placebo or a single-stage combination and optionally the pharmaceutically harmless placebo-containing or placebo- and hormone-free daily dose units amounts to 28 daily dose units.
Public/Granted literature
Information query
